Amyloid Related Imaging Abnormalities

General Overview for the Emergency Physician

Amyloid Related Imaging Abnormalities (ARIA)

- A **spectrum** of **MRI signal abnormalities** associated with **amyloid clearance** in the **brain**[1-3]
- Can occur spontaneously but more frequently observed during treatment with **amyloid targeting therapies**[1-3]
- There are two types of ARIA: **ARIA-E** and **ARIA-H**[2-4]
  - Both types may be observed on the same scan[5]
  - ARIA type is determined by nature of **leakage product** and **location**[2,5]
- **Monoclonal antibodies** directed against aggregated forms of beta amyloid carry a boxed warning regarding the **increased risk for causing ARIA**, which can be serious and life threatening[1-3]
- **Identification of ARIA** prior to initiation of therapy and ongoing **monitoring via MRI** imaging are crucial during treatment with amyloid targeting therapies[1-3]

ARIA-E Vasogenic Edema and/or Sulcal Effusion

ARIA-H Hemosiderin Deposits



Parenchymal hyperintense signal on T2 FLAIR

Leptomeningeal sulcal surface hyperintense signal on T2 FLAIR

Punctate foci of signal void on T2* GRE

Sulcal signal hypointensity on T2* GRE

Figure adapted from Barakos J et al. J Prev Alz Dis. 2022;9:211-220. Copyright © licensed under CC-BY-4.0 (https://creativecommons.org/licenses/by/4.0/). Modified from original by cutting.

Radiographic Severity Monitoring[5]

	Mild	Moderate	Severe
ARIA-E: Sulcal and/or cortical/subcortical FLAIR hyperintensity Measured in single greatest dimension	1 site <5 cm	1 site 5-10 cm, or >1 site each <10 cm	≥1 site(s) >10 cm
ARIA-H: Number of new* microhemorrhages	≤4	5-9	≥10
ARIA-H: Superficial siderosis	1 focal area	2 focal areas	>2 focal areas

*New: cumulative number from baseline

Clinical Symptom Severity Monitoring[6-8]

Asymptomatic:
No symptoms noted, no disruption of daily activities

Mild:
Symptoms noted, no disruption of daily activities

Moderate:
Symptoms sufficient to reduce or affect normal daily activities

Severe:
Incapacitating with inability to perform normal daily activities

Common
- Headache
- Confusion/ Dizziness
- Nausea

Less common
- Neuropsychiatric symptoms
- Visual disturbance/ Blurred vision
- Gait disturbance

Least common
- Seizure/status epilepticus, encephalopathy, stupor, coma, stroke-like symptoms/focal neurological deficits

ARIA Monitoring and Management: General Principles[1-3, 6-8]

- Baseline ARIA evaluation and periodic monitoring with MRI are recommended during treatment with amyloid targeting therapies
- Refer to prescribing information for monoclonal antibodies directed against beta amyloid for ARIA monitoring and management guidelines
- Patients experiencing symptoms suggestive of ARIA should undergo clinical evaluation immediately, including MRI if indicated
- If ARIA is observed on MRI, careful clinical evaluation should be performed. Dose suspension or discontinuation may be considered based on the presence of symptoms and/or radiographic severity
- If required, treatment of ARIA revolves around close monitoring of neurologic status and administration of supportive therapy, which may include corticosteroids
- There is limited experience in patients who continued dosing through ARIA-E
- There is limited data for dosing patients who experienced recurrent episodes of ARIA-E

Abbreviations: **ARIA-E** = Amyloid Related Imaging Abnormalities-Edema/Effusion; **ARIA-H** = Amyloid Related Imaging Abnormalities-Hemosiderin deposits; **FLAIR** = Fluid-Attenuated Inversion Recovery; **GRE** = Gradient Recalled Echo; **MRI** = Magnetic Resonance Imaging.

1. Salloway S, MD et al. JAMA Neurol. 2022;79:13-21. **2.** Filippi M et al. JAMA Neurol. 2022;79:291-304. **3.** Sperling RA et al. Alzheimer's Dement. 2011;7:367-385. **4.** Figure adapted from Barakos J et al. J Prev Alz Dis. 2022;9:211-220. Copyright © licensed under CC-BY-4.0 (https://creativecommons.org/licenses/by/4.0/). Modified from original by cutting. **5.** Cogswell PM et al. Am J Neurol. 2022;43:e19-35. **6.** Cummings J et al. J Prev Alz Dis. 2023;10:362-377. **7.** Cummings J et al. J Prev Alz Dis. 2022;9:221-230. **8.** Cummings J et al. J Prev Alz Dis. 2021;4:398-410.

Amyloid Related Imaging Abnormalities

ARIA-E versus ARIA-H

- There are two types of Amyloid Related Imaging Abnormalities (ARIA): **ARIA-E** and **ARIA-H**[1]
  - **ARIA-E** visualized on MRI as **signal hyperintensity** on **T2 FLAIR**[2]
  - **ARIA-H** visualized on MRI as **signal hypointensity** by use of **GRE/T2*** or **SWI sequences**[2]

Edema[1]



ARIA-Edema example image: Hyperintensity on T2 FLAIR in left parieto-occipital lobe, consistent with parenchymal edema

Effusion[1]

ARIA-Effusion example image: Hyperintensity on T2 FLAIR in the sulci within the right temporo-occipital lobe, consistent with effusion

ARIA-E Vasogenic Edema and/or Sulcal Effusion[2,3]

Nature of leakage products	Proteinaceous fluids
Location of increased vascular permeability	**Parenchyma:** vasogenic edema **Leptomeninges:** sulcal effusions (i.e., exudates)
Primary diagnostic imaging sequence	T2 FLAIR
Evaluation of severity	MRI severity scales[4]

Microhemorrhage[1]

ARIA-Microhemorrhage example image: Punctate foci of signal void on T2* GRE in an area of parenchymal edema, consistent with microhemorrhage

Superficial Siderosis[1]

ARIA-Siderosis example image: Signal hypointensity in the left frontal area on T2* GRE, consistent with superficial siderosis on axial

ARIA-H Hemosiderin Deposits[2,3]

Nature of leakage products	Blood-degradation products
Location of increased vascular permeability	**Parenchyma:** microhemorrhage (<10 mm) and intracerebral hemorrhage (≥10 mm) **Leptomeninges:** superficial hemosiderin deposits (superficial siderosis)
Primary diagnostic imaging sequence	T2* GRE and/or SWI
Evaluation of severity	Number of microhemorrhages and hemosiderin deposits on MRI

Abbreviations: **ARIA-E** = Amyloid Related Imaging Abnormalities-Edema/Effusion; **ARIA-H** = Amyloid Related Imaging Abnormalities-Hemosiderin deposits; **FLAIR** = Fluid-Attenuated Inversion Recovery; **GRE** = Gradient Recalled Echo; **MRI** = Magnetic Resonance Imaging. **SWI** = Susceptibility Weighted Imaging.

1. Figure adapted from Barakos J et al. J Prev Alz Dis. 2022;9:211-220. Copyright © licensed under CC-BY-4.0 (https://creativecommons.org/licenses/by/4.0/). Modified from original by cutting. **2.** Barakos J et al. Am J Neuroradiol. 2013;34:1958-1965. **3.** Sperling RA et al. Alzheimer's Dement. 2011;7:367-385. **4.** Barkhof F et al. Am J Neurol. 2013;34:1550-1555.

Amyloid Related Imaging Abnormalities

Detecting ARIA: Recommended MRI Protocol[2]

Scan the QR-code or copy/paste the link to access an ARIA MRI Protocol Overview

Scan the QR code or copy/ paste the link to access a standardized reporting template for ARIA MRI imaging, recommended by ASNR

- Imaging protocol standardization is necessary to ensure consistent accuracy in diagnosing ARIA, and specific parameters are needed to achieve cross-platform standardization[1]

3T scanner (recommended), 1.5T scanner (minimal)[1,2]	High field scanners have greater sensitivity but limited availability. The use of 1.5T is endorsed as a minimum standard[2]
Slice thickness[2]: ≤5 mm	Thinner slices increase resolution but should be balanced against the loss in signal-to-noise ratio[2]
TE[2]: ≥20 ms	Longer TE increases sensitivity to detection[2]
2D T2* GRE or SWI (for ARIA-H)[2,3]	To identify superficial siderosis and microhemorrhages (ARIA-H) T2* GRE and SWI MRI sequences are used to improve detection and visualization of microhemorrhages[2]
T2 FLAIR (for ARIA-E)[2]	To monitor brain edema or sulcal effusion (ARIA-E)[3]
DWI[3]	Recommended for differential diagnosis[3]
3D T1-GE (optional)[1]	Anatomical[1]

Abbreviations: **ARIA-E** = Amyloid Related Imaging Abnormalities-Edema/Effusion; **ARIA-H** = Amyloid Related Imaging Abnormalities-Hemosiderin deposits; **DWI** = Diffusion Weighted Imaging; **FLAIR** = Fluid-Attenuated Inversion Recovery; **GRE** = Gradient Recalled Echo; **MRI** = Magnetic Resonance Imaging. **SWI** = Susceptibility Weighted Imaging; **TE** = Time to Echo.

1. Pinter NK et al. Alzheimer's Dement. 2022;18(Suppl. 5):e065547. **2.** Cogswell PM et al. Am J Neurol. 2022;43:e19-35. **3.** Sperling RA et al. Alzheimer's Dement. 2011;7:367-385. **4.** Barakos J et al. J Prev Alz Dis. 2022;9:211-220.